Beijing Aosaikang Pharmaceutical (002755.SZ): Innovative drug ASKB589 to release clinical research data at the 2025 ESMO Annual Meeting.

Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its subsidiary, ASKGENE LIMITED, presented the latest research results of the investigational biologic drug ASKB589 (targeting CLDN18.2 monoclonal antibody) combined with CAPOX and PD-1 inhibitor in the first-line treatment of advanced gastric cancer at the European Society for Medical Oncology (ESMO) annual meeting held in Berlin, Germany on October 19, 2025. The phase Ib/II clinical study of ASKB589 (targeting CLDN18.2 monoclonal antibody) combined with CAPOX (oxaliplatin and capecitabine) and PD-1 inhibitor in the first-line treatment of locally advanced, recurrent or metastatic adenocarcinoma of the stomach and esophagogastric junction cancer patients showed continued deep and durable tumor remission and disease control in longer-term follow-up. It also demonstrated clear survival benefits, supporting the ongoing pivotal phase III clinical study of ASKB589 combined with chemotherapy and PD-1 inhibitor. The data of the ASKB589 triple combination therapy presented at the ESMO conference further confirmed its significant and durable anti-tumor activity, and for the first time disclosed overall survival (OS) benefits in patients with advanced first-line gastric cancer. The positive clinical data will help enhance the future market competitiveness of the company's products.